Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Patients' expression of CEACAM5 might hold the key to activity after all.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.